Ability Pharmaceuticals enters into a licensing agreement with SciClone Pharmaceuticals for the novel anticancer agent ABTL0812 for the China market

by AbilityPharma

Collaboration boosts development of a fully differentiated inhibitor of the PI3K/Akt/mTOR pathway. ABTL0812 is currently in Phase 2 clinical trials to treat lung and endometrial cancers.

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Telum Therapeutics Secures €18 Million...

by Telum Therapeutics

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream